The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InShares of BDX, SHOO, and BRKR climbed following quarterly results that surpassed estimates, with BDX reporting Q2 revenue of $4.7 billion. Although BDX posted an EPS loss of $0.13, the results were impacted by a significant $1.6 billion one-off loss and a $274 million loss from discontinued operations. Meanwhile, Steven Madden shares surged 6% after upwardly revising its 2026 revenue guidance, and Bruker reported strong results fueled by robust growth in European operations. Madrigal Pharmaceuticals (MDGL) also maintained its momentum, supported by robust sales of Rezdiffra amid growing demand for MASH treatments. This performance across the healthcare and consumer sectors reflects organic growth momentum despite specific accounting headwinds. The combination of raised forward guidance and resilient revenue figures continues to generate optimism in the market.